搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 24 小时
时间不限
过去 1 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
Zacks.com on MSN
2 小时
EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease
The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or ...
BioSpace
2 小时
AbbVie Continues Deal-Making Spree With $200M Nimble Buy
The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and ...
manilatimes
2 小时
Qu Biologics' Site Specific Immunomodulator Enables CAR T-cell Cancer Efficacy in Solid Tumor
Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel ...
HealthPrep on MSN
18 小时
11 Whey Cool Reasons Your Body Craves Protein Power
As the name implies, whey protein is the edible protein found in whey, the watery part of milk that becomes separated from ...
6 小时
Jane Street Group LLC Sells 98,683 Shares of Option Care Health, Inc. (NASDAQ:OPCH)
Jane Street Group LLC decreased its stake in shares of Option Care Health, Inc. (NASDAQ:OPCH – Free Report) by 33.6% during ...
Pharmaceutical Technology
22 小时
Risk adjusted net present value: What is the current valuation of I-Mab’s Givastomig?
The revenue for Givastomig is expected to reach an annual total of $48 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈